Pharmafile Logo

meningitis B

Accelerating Drug Development Timelines with Big Data Analytics

Barış Erdoğan, CEO of Clinerion, shares how medical data informatics and real-world EHR data can be used to improve the efficiency and effectiveness of patient searches, identification, and recruitment; clinical...

Impetus Digital

Health literacy in the time of COVID-19

In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...

Impetus Digital

- PMLiVE

South Korean company SK bioscience moves into phase 3 trials for its COVID-19 vaccine

Part of the Wave 2 vaccine programme, GBP510 will bolster South Korea’s domestic supply if successful

- PMLiVE

GSK beats expectations thanks to strong vaccine sales in Q2

GSK's vaccine business was up by 39% to £1.6bn thanks to the strong growth (46%) of its meningitis vaccine

- PMLiVE

EMA begins rolling review of Sanofi, GSK’s COVID-19 vaccine

Rolling review launched based on preliminary results from lab studies and early clinical studies

- PMLiVE

GSK reveals plans for £400m R&D facility expansion in England

GSK has formally started the process of seeking a development partner for the expansion plans

- PMLiVE

GSK supports CEO Emma Walmsley following Elliott’s demands for leadership overhaul

GSK’s board said that it ‘strongly believes’ Walmsley is the ‘right leader’ for the new biopharma business

- PMLiVE

GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

The focus of the deal is two clinical-stage monoclonal antibodies in development for a number of neurodegenerative diseases

- PMLiVE

Elliott Management puts pressure on GSK after years of ‘disappointing performance’

Hedge fund has published a 17-page letter outlining recommendations following GSK's investor day last week

- PMLiVE

WHITE PAPER: From bench to bedside in one year – how the race for a COVID-19 vaccine will change the future of drug development

In this edition of MAGNIFI, we discuss the factors behind this acceleration in development of the COVID-19 vaccines and what this might mean for the future of pharma

IGNIFI

- PMLiVE

GSK aims for £33bn in sales by 2031 as CEO Walmsley lays out ten-year strategy

'New' GSK will build on growth potential of its vaccines and speciality medicines portfolios

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links